已收录 268921 条政策
 政策提纲
  • 暂无提纲
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery
[摘要] Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI/kg every 28±2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 血液学
[关键词] Recombinant FXIII;congenital FXIII deficiency;surgery [时效性] 
   浏览次数:15      统一登录查看全文      激活码登录查看全文